Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 5:01 Acquisition Corp.FVAM · Entity 144989 | Director | October 16, 2020 | October 21, 2020 |
| ALEXION PHARMACEUTICALS, INC.ALXN · Entity 137086 | EVP & Global Head of R&D | February 27, 2017 | March 01, 2017 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | May 08, 2026 | May 11, 2026 |
| Kailera Therapeutics, Inc.KLRA · Entity 4435 | Director | April 16, 2026 | April 20, 2026 |
| PFIZER INCPFE · Entity 2863 | Senior Vice President | May 14, 2010 | May 18, 2010 |
| Rallybio CorpRLYB · Entity 6838 | Director | February 18, 2026 | February 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
5:01 Acquisition Corp.
Report date October 16, 2020 · Filed October 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 30,000 |
Reported balance
After 2020-10-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-16 · Other · Acquired 30,000 · Balance 30,000 F1: The shares of Class B common stock are automatically convertible into the issuer's shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The shares of Class B common stock are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the issuer's Board of Directors. F2: In connection with the issuer's initial public offering and the Reporting Person's appointment to the issuer's Board of Directors, 5:01 Acquisition LLC transferred 30,000 shares of Class B common stock to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock are automatically convertible into the issuer's shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The shares of Class B common stock are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the issuer's Board of Directors.
F2: In connection with the issuer's initial public offering and the Reporting Person's appointment to the issuer's Board of Directors, 5:01 Acquisition LLC transferred 30,000 shares of Class B common stock to the Reporting Person.
ALEXION PHARMACEUTICALS, INC.
Report date February 27, 2017 · Filed March 01, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 50,688 |
Ending reported balance
After 2017-03-01 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2017-02-27 · Sale · Disposed 860 · Balance 38,883 F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Row 2 · 2017-02-28 · Sale · Disposed 625 · Balance 38,258 F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Row 3 · 2017-02-28 · Grant · Acquired 12,800 · Balance 51,058 F3: Award of Restricted Stock Units under the 2004 Incentive Plan. 25% vests on each anniversary of the grant date. Row 4 · 2017-03-01 · Sale · Disposed 370 · Balance 50,688 F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F4: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $132.00 - $132.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $131.25 · Expires 2027-02-28 | Direct | 12,800 |
Reported balance
After 2017-02-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-02-28 · Grant · Acquired 12,800 · Balance 12,800 F5: Stock option award under 2004 Incentive Plan. 25% vest on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.
F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
F3: Award of Restricted Stock Units under the 2004 Incentive Plan. 25% vests on each anniversary of the grant date.
F4: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $132.00 - $132.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
F5: Stock option award under 2004 Incentive Plan. 25% vest on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date May 08, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,137 |
Ending reported balance
After 2026-05-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-08 · Grant · Acquired 1,438 · Balance 15,730 F1: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders. Row 2 · 2026-05-08 · Grant · Acquired 1,407 · Balance 17,137 F2: The grant was made in lieu of director service fees for the term commencing May 5, 2026. The restricted stock units vest upon the earlier of 5/8/2027, or the business day prior to the Company's next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.
F2: The grant was made in lieu of director service fees for the term commencing May 5, 2026. The restricted stock units vest upon the earlier of 5/8/2027, or the business day prior to the Company's next annual meeting of shareholders.
Kailera Therapeutics, Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 38,300 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 38,300 · Balance 38,300 F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.
PFIZER INC
Report date May 14, 2010 · Filed May 18, 2010
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock Units SSPSEC Table II · derivative / convertible security | Direct | 10,637 |
Reported balance
After 2010-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2010-05-14 · Grant · Acquired 236 · Balance 10,637 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Rallybio Corp
Report date February 18, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.45 · Expires 2036-02-18 | Direct | 18,055 |
Reported balance
After 2026-02-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-18 · Grant · Acquired 18,055 · Balance 18,055 F1: The option vests as to the underlying shares of Common Stock in 11 equal installments, each on the last day of each remaining month of calendar year 2026. F2: This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $65,000. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to the underlying shares of Common Stock in 11 equal installments, each on the last day of each remaining month of calendar year 2026.
F2: This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $65,000.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SpringWorks Therapeutics, Inc.
Report date July 01, 2025 · Filed July 02, 2025
Section 16 reporting ended · disclosed 2025-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 1
1 source rowRow 1 · 2025-07-01 · Disposition to issuer · Disposed 20,023 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F2: Represents shares underlying restricted stock units (each, an "RSU") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Issuer common stock. F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the "Merger Consideration"). F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a "Parent Cash-Based RSU Award"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.80 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-01 · Disposition to issuer · Disposed 29,445 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6) F6: (Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger").
F2: Represents shares underlying restricted stock units (each, an "RSU") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Issuer common stock.
F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the "Merger Consideration").
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a "Parent Cash-Based RSU Award"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)
F6: (Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2026 Filed May 11, 2026 20:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,407 | $177.62 | $249,911.34 |
DisclosureSEC source: 0001100682-26-000059 · form4.xml · nonDerivative · entry 2 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,137 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 5, 2026. The restricted stock units vest upon the earlier of 5/8/2027, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 08, 2026 Filed May 11, 2026 20:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,438 | $177.62 | $255,417.56 |
DisclosureSEC source: 0001100682-26-000059 · form4.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,730 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 21:10 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | GrantStock Option (right to buy) · Derivative | 38,300 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-164253 · ownership.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,300 Underlying: Common Stock · 38,300 shares Expires 2036-04-16 F1 · derivative.exercise_date: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 23:08 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 18,055 | $3.60 Strike: $4.45 | $64,998.00 |
DisclosureSEC source: 0001628280-26-010334 · wk-form4_1771628906.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,055 Underlying: Common Stock · 18,055 shares Expires 2036-02-18 F1 · derivative.exercise_date: The option vests as to the underlying shares of Common Stock in 11 equal installments, each on the last day of each remaining month of calendar year 2026. F2 · derivative.underlying_shares: This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $65,000. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:21 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 29,445 | Not disclosed Strike: $36.80 | Not disclosed |
DisclosureSEC source: 0001104659-25-065304 · tm2519678-7_4seq1.xml · derivative · entry 2 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,445 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6) F6 · price: (Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6) F6 · derivative.exercise_date: (Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6) F6 · derivative.expiration_date: (Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:21 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | Disposition to issuerCommon Stock | 20,023 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-065304 · tm2519678-7_4seq1.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F2 · shares: Represents shares underlying restricted stock units (each, an "RSU") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Issuer common stock. F3 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the "Merger Consideration"). F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a "Parent Cash-Based RSU Award"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 2,076 | $134.98 Strike: $134.98 | $280,218.48 |
DisclosureSEC source: 0001127602-25-015485 · form4.xml · derivative · entry 3 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,076 Underlying: Common Stock · 2,076 shares Expires 2035-05-21 F3 · shares: The stock options become exercisable upon the earlier of 5/21/2026 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 815 | $134.98 | $110,008.70 |
DisclosureSEC source: 0001127602-25-015485 · form4.xml · nonDerivative · entry 2 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,292 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 20, 2025. The restricted stock units vest upon the earlier of 5/21/2026, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 946 | $134.98 | $127,691.08 |
DisclosureSEC source: 0001127602-25-015485 · form4.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,477 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/21/2026 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 14, 2025 Filed May 15, 2025 22:40 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantCommon Stock | 10,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-049655 · tm2515271-1_4seq1.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,023 F1 · kind: This transaction represents a grant of restricted stock units ("RSUs") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (i) May 14, 2026 and (ii) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person. Read SEC document |
| May 13, 2025 Filed May 15, 2025 21:00 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 28,500 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001739410-25-000080 · wk-form4_1747342769.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2035-05-13 F1 · derivative.exercise_date: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:07 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 92,857 | $0.70 Strike: $0.95 | $64,999.90 |
DisclosureSEC source: 0001739410-25-000008 · wk-form4_1736201245.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,857 Underlying: Common Stock · 92,857 shares Expires 2035-01-02 F2 · price: This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $65,000. F1 · derivative.exercise_date: The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2025. Read SEC document |
| July 29, 2024 Filed Jul 30, 2024 20:10 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantStock Option (Right to Buy) · Derivative | 29,445 | $0.00 Strike: $36.80 | $0.00 |
DisclosureSEC source: 0001104659-24-083966 · tm2420483-2_4seq1.xml · derivative · entry 2 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,445 Underlying: Common Stock · 29,445 shares Expires 2034-07-29 F2 · kind: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for initial equity grants to the Issuer's non-employee directors on the date of the Reporting Person's commencement of service to the Issuer. F3 · derivative.exercise_date: The options shall vest in equal monthly installments over 36 months following July 29, 2024, subject to continued service to the Issuer by the Reporting Person. Read SEC document |
| July 29, 2024 Filed Jul 30, 2024 20:10 UTC | SpringWorks Therapeutics, Inc. SWTX · Entity 15910 | GrantCommon Stock | 9,963 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-083966 · tm2420483-2_4seq1.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,963 F1 · kind: This transaction represents a grant of restricted stock units ("RSUs") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for initial equity grants to the Issuer's non-employee directors on the date of the Reporting Person's commencement of service to the Issuer. The RSUs shall vest in three (3) equal annual installments following July 29, 2024, subject to continued service to the Issuer by the Reporting Person. Read SEC document |
| May 13, 2024 Filed May 15, 2024 21:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,311 | $228.41 Strike: $228.41 | $299,445.51 |
DisclosureSEC source: 0001127602-24-015531 · form4.xml · derivative · entry 3 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,311 Underlying: Common Stock · 1,311 shares Expires 2034-05-13 F3 · shares: The stock options become exercisable upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 13, 2024 Filed May 15, 2024 21:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 372 | $228.41 | $84,968.52 |
DisclosureSEC source: 0001127602-24-015531 · form4.xml · nonDerivative · entry 2 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,531 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 8, 2024. The restricted stock units vest upon the earlier of 5/13/2025, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 13, 2024 Filed May 15, 2024 21:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 559 | $228.41 | $127,681.19 |
DisclosureSEC source: 0001127602-24-015531 · form4.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,159 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 23:21 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 216,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001739410-24-000019 · wk-form4_1708125672.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,000 Underlying: Common Stock · 216,000 shares Expires 2034-02-15 F1 · derivative.exercise_date: The option is granted under the Company's 2021 Equity Incentive Plan. The option vests in 48 equal monthly installments until fully vested on February 15, 2028. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 19:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 95 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019952 · form4.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,600 F1 · shares: The grant was made in lieu of director service fees for the term commencing May 9, 2023. The restricted stock units vest the earlier of July 3, 2024 and the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 14:22 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 338 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-017435 · form4.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,505 F1 · shares: The grant was made in lieu of director service fees for the term commencing May 9, 2023. The restricted stock units vest upon the earlier of 5/15/2023 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 15, 2023 Filed May 17, 2023 18:43 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,669 | $192.36 Strike: $192.36 | $321,048.84 |
DisclosureSEC source: 0001127602-23-015850 · form4.xml · derivative · entry 2 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,669 Underlying: Common Stock · 1,669 shares Expires 2033-05-15 F2 · shares: The Stock Options become exercisable upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 15, 2023 Filed May 17, 2023 18:43 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 664 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-015850 · form4.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,167 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| February 06, 2023 Filed Feb 6, 2023 22:39 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 214,000 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0000899243-23-004074 · doc4.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,000 Underlying: Common Stock · 214,000 shares Expires 2033-02-06 F1 · derivative.exercise_date: The option is granted under the Company's 2021 Equity Incentive Plan. The option vests in 48 equal monthly installments until fully vested on February 6, 2027. Read SEC document |
| May 11, 2022 Filed May 13, 2022 20:57 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,512 | $222.31 Strike: $222.31 | $336,132.72 |
DisclosureSEC source: 0001127602-22-014473 · form4.xml · derivative · entry 3 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,512 Underlying: Common Stock · 1,512 shares Expires 2032-05-11 F3 · shares: The Stock Options become exercisable upon the earlier of 5/11/2023 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2022 Filed May 13, 2022 20:57 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 292 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-014473 · form4.xml · nonDerivative · entry 2 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,503 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 10, 2022. The restricted stock units vest upon the earlier of 5/11/2023, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2022 Filed May 13, 2022 20:57 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 549 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-014473 · form4.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,211 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/11/2023 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| February 07, 2022 Filed Feb 10, 2022 00:38 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0000899243-22-005519 · doc4.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2032-02-07 F1 · derivative.exercise_date: The option is granted under the Company's 2021 Equity Incentive Plan. The option vests in 48 equal monthly installments until fully vested on February 7, 2026. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 23:56 UTC | Rallybio Corp RLYB · Entity 6838 | PurchaseCommon Stock | 4,496 | $10.65 | $47,882.40 |
DisclosureSEC source: 0000899243-22-001801 · doc4.xml · nonDerivative · entry 4 MACKAY MARTIN · CIK 0001414815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,609 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.01 to $11.00, inclusive. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 23:56 UTC | Rallybio Corp RLYB · Entity 6838 | PurchaseCommon Stock | 5,504 | $10.10 | $55,590.40 |
DisclosureSEC source: 0000899243-22-001801 · doc4.xml · nonDerivative · entry 3 MACKAY MARTIN · CIK 0001414815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,113 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.66 to $10.65, inclusive. The reporting person undertakes to provide to Rallybio Corporation, any security holder of Rallybio Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 22:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 63 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-000559 · form4.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,662 F1 · shares: The grant was made in lieu of director service fees. The restricted stock units vest upon the earlier of 5/7/2022, or the business day prior to the Company's next annual meeting. Read SEC document |
| July 28, 2021 Filed Jan 12, 2022 23:56 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001801 · doc4.xml · derivative · entry 10 MACKAY MARTIN · CIK 0001414815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2031-07-28 F5 · derivative.exercise_date: The option vests as to 25% of the underlying shares of Common Stock on July 28, 2022 and as to the remaining 75% of the underlying shares of Common Stock in 36 equal monthly installments thereafter. Read SEC document |
| July 28, 2021 Filed Jan 12, 2022 23:56 UTC | Rallybio Corp RLYB · Entity 6838 | OtherSeries B Preferred Units · Derivative | 107,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-001801 · doc4.xml · derivative · entry 9 MACKAY MARTIN · CIK 0001414815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 16,944 shares Expires not disclosed F1 · derivative.exercise_price: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · kind: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · price: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · derivative.exercise_date: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · derivative.expiration_date: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F2 · ownership.nature: Shares of common stock are held directly by a limited liability company, of which Martin Mackay is the managing member. As a result, Dr. Mackay may be deemed to share beneficial ownership of the shares held by the limited liability company. Read SEC document |
| July 28, 2021 Filed Jan 12, 2022 23:56 UTC | Rallybio Corp RLYB · Entity 6838 | OtherSeries A-2 Preferred Units · Derivative | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-001801 · doc4.xml · derivative · entry 8 MACKAY MARTIN · CIK 0001414815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 15,704 shares Expires not disclosed F1 · derivative.exercise_price: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · kind: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · price: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · derivative.exercise_date: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · derivative.expiration_date: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F2 · ownership.nature: Shares of common stock are held directly by a limited liability company, of which Martin Mackay is the managing member. As a result, Dr. Mackay may be deemed to share beneficial ownership of the shares held by the limited liability company. Read SEC document |
| July 28, 2021 Filed Jan 12, 2022 23:56 UTC | Rallybio Corp RLYB · Entity 6838 | OtherSeries A-1 Preferred Units · Derivative | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-001801 · doc4.xml · derivative · entry 7 MACKAY MARTIN · CIK 0001414815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 23,557 shares Expires not disclosed F1 · derivative.exercise_price: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · kind: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · price: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · derivative.exercise_date: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · derivative.expiration_date: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F2 · ownership.nature: Shares of common stock are held directly by a limited liability company, of which Martin Mackay is the managing member. As a result, Dr. Mackay may be deemed to share beneficial ownership of the shares held by the limited liability company. Read SEC document |
| July 28, 2021 Filed Jan 12, 2022 23:56 UTC | Rallybio Corp RLYB · Entity 6838 | OtherCommon Units · Derivative | 2,564,999 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-001801 · doc4.xml · derivative · entry 6 MACKAY MARTIN · CIK 0001414815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 380,312 shares Expires not disclosed F1 · derivative.exercise_price: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · kind: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · price: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · derivative.exercise_date: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · derivative.expiration_date: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F2 · ownership.nature: Shares of common stock are held directly by a limited liability company, of which Martin Mackay is the managing member. As a result, Dr. Mackay may be deemed to share beneficial ownership of the shares held by the limited liability company. Read SEC document |
| July 28, 2021 Filed Jan 12, 2022 23:56 UTC | Rallybio Corp RLYB · Entity 6838 | OtherCommon Units · Derivative | 2,255,001 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-001801 · doc4.xml · derivative · entry 5 MACKAY MARTIN · CIK 0001414815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 272,609 shares Expires not disclosed F1 · derivative.exercise_price: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · kind: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · price: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · derivative.exercise_date: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · derivative.expiration_date: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. Read SEC document |
| July 28, 2021 Filed Jan 12, 2022 23:56 UTC | Rallybio Corp RLYB · Entity 6838 | OtherCommon Stock | 436,517 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-001801 · doc4.xml · nonDerivative · entry 2 MACKAY MARTIN · CIK 0001414815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 436,517 F1 · kind: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · price: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F2 · ownership.nature: Shares of common stock are held directly by a limited liability company, of which Martin Mackay is the managing member. As a result, Dr. Mackay may be deemed to share beneficial ownership of the shares held by the limited liability company. Read SEC document |
| July 28, 2021 Filed Jan 12, 2022 23:56 UTC | Rallybio Corp RLYB · Entity 6838 | OtherCommon Stock | 272,609 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-001801 · doc4.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,609 F1 · kind: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. F1 · price: The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,151 | $0.00 Strike: $342.55 | $0.00 |
DisclosureSEC source: 0001127602-21-016109 · form4.xml · derivative · entry 3 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151 Underlying: Common Stock · 1,151 shares Expires 2031-05-07 F3 · shares: The Stock Options become exercisable upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 219 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-016109 · form4.xml · nonDerivative · entry 2 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,599 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 5, 2021. The restricted stock units vest upon the earlier of 5/7/2021, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 355 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-016109 · form4.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,380 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| October 16, 2020 Filed Oct 21, 2020 00:52 UTC | 5:01 Acquisition Corp. FVAM · Entity 144989 | OtherClass B Common Stock · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-055438 · doc4.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Class A Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: The shares of Class B common stock are automatically convertible into the issuer's shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The shares of Class B common stock are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the issuer's Board of Directors. F2 · kind: In connection with the issuer's initial public offering and the Reporting Person's appointment to the issuer's Board of Directors, 5:01 Acquisition LLC transferred 30,000 shares of Class B common stock to the Reporting Person. F1 · derivative.exercise_date: The shares of Class B common stock are automatically convertible into the issuer's shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The shares of Class B common stock are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the issuer's Board of Directors. F1 · derivative.expiration_date: The shares of Class B common stock are automatically convertible into the issuer's shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The shares of Class B common stock are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the issuer's Board of Directors. Read SEC document |
| May 11, 2020 Filed May 12, 2020 18:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 2,539 | $0.00 Strike: $164.24 | $0.00 |
DisclosureSEC source: 0001127602-20-016250 · form4.xml · derivative · entry 3 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,539 Underlying: Common Stock · 2,539 shares Expires 2030-05-11 F3 · derivative.exercise_date: The Stock Options become exercisable upon the earlier of 5/11/2021 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2020 Filed May 12, 2020 18:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 457 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-016250 · form4.xml · nonDerivative · entry 2 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,025 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 6, 2020. The restricted stock units vest upon the earlier of 5/11/2021, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2020 Filed May 12, 2020 18:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 741 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-016250 · form4.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,568 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/11/2021 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 22, 2019 Filed May 23, 2019 17:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 599 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-019568 · form4.xml · nonDerivative · entry 2 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,827 F2 · kind: This grant was made in lieu of director service fees for the term commencing May 21, 2019. The restricted stock units vest upon the earlier of 5/22/2020, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 22, 2019 Filed May 23, 2019 17:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-019568 · form4.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,228 F1 · kind: Consists of 1,882 unvested restricted stock units that vest upon the earlier of 5/22/2020, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 14, 2018 Filed May 16, 2018 10:43 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-017568 · form4.xml · nonDerivative · entry 2 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,346 F2 · kind: This grant was made in lieu of director service fees for the term commencing May 8, 2018. The restricted stock units vest upon the earlier of 5/14/2019 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 14, 2018 Filed May 16, 2018 10:43 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,004 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-017568 · form4.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,786 F1 · kind: Consists of 2,004 unvested restricted stock units that vest upon the earlier of 5/14/2019, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 12:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 607 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-024821 · form4.xml · nonDerivative · entry 2 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,782 F2 · kind: This grant was made in lieu of cash for director service fees for the term commencing July 1, 2017. The restricted stock units vest on 8/1/2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.